Stuart Poulton - Feb 15, 2024 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role
EVP, Chief Development Officer
Signature
Nancy Smith as Attorney-in-Fact for Stuart Poulton
Stock symbol
KPTI
Transactions as of
Feb 15, 2024
Transactions value $
-$7,783
Form type
4
Date filed
2/20/2024, 04:59 PM
Previous filing
Jan 25, 2024
Next filing
Feb 29, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KPTI Common Stock Sale -$7.64K -5.75K -3.39% $1.33 164K Feb 15, 2024 Direct F1
transaction KPTI Common Stock Sale -$139 -99 -0.06% $1.40 164K Feb 15, 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.